Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Colorado Springs

A Phase 2, Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

  • Details

ClinicalTrials.gov ID: NCT05577715
Diagnosis Type: Lung Cancer
USOR Number: 22107

  • Practice Details

2312 N Nevada Ave, Suite 400
Colorado Springs, CO 80907
P: (719) 577-2555

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 2, Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

  • Details

ClinicalTrials.gov ID: NCT05577715
Diagnosis Type: Lung Cancer
USOR Number: 22107

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, CO 80220
P: (303) 321-0302

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 2, Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

  • Details

ClinicalTrials.gov ID: NCT05577715
Diagnosis Type: Lung Cancer
USOR Number: 22107

  • Practice Details

1800 Williams St, Suite 200
Denver, CO 80218
P: (303) 388-4876

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Aurora

A Phase 2, Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

  • Details

ClinicalTrials.gov ID: NCT05577715
Diagnosis Type: Lung Cancer
USOR Number: 22107

  • Practice Details

1700 S Potomac Street
Aurora, CO 80012
P: (303) 418-7600

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase 2, Open-Label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (CA116-003)

  • Details

ClinicalTrials.gov ID: NCT05577715
Diagnosis Type: Lung Cancer
USOR Number: 22107

  • Practice Details

4715 Arapahoe Avenue
Boulder, CO 80303
P: (303) 385-2000

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Thornton

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

  • Details

ClinicalTrials.gov ID: NCT05514054
Diagnosis Type: Breast Cancer
USOR Number: 22101

  • Practice Details

8820 Huron St
Thornton, CO 80260
P: (303) 386-7622

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Lakewood

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

  • Details

ClinicalTrials.gov ID: NCT05514054
Diagnosis Type: Breast Cancer
USOR Number: 22101

  • Practice Details

11750 W 2nd Place, Suite 160
Lakewood, CO 80228
P: (303) 430-2700

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Littleton

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

  • Details

ClinicalTrials.gov ID: NCT05514054
Diagnosis Type: Breast Cancer
USOR Number: 22101

  • Practice Details

22 W Dry Creek Circle
Littleton, CO 80120
P: (303) 730-4700

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Lone Tree

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

  • Details

ClinicalTrials.gov ID: NCT05514054
Diagnosis Type: Breast Cancer
USOR Number: 22101

  • Practice Details

10107 RidgeGate Parkway, Suite 200
Lone Tree, CO 80124
P: (303) 925-0700

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

  • Details

ClinicalTrials.gov ID: NCT05514054
Diagnosis Type: Breast Cancer
USOR Number: 22101

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, CO 80220
P: (303) 321-0302

More Details View Practice Page
1 … 5 6 7 8 9 … 64

Find a Location

With more than 1,400 physicians and over 500 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.